Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401985 · ClinicalTrials.gov registry record · Phase 2
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Phase 2 study of Opioid-induced Constipation, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT01401985 is a Phase 2 study of Opioid-induced Constipation that has completed, run by Theravance Biopharma. The registered enrollment target is 95 participants, below the 7,213-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01401985, a Phase 2 study of Opioid-induced Constipation, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1211
Study Locations (1)
California
- Theravance Biopharma Investigational Site - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401985
The ClinicalTrials.gov registry entry for NCT01401985 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,213-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (99% lower). The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-induced Constipation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01401985 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01401985 about?
NCT01401985 is a clinical study titled "A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)". A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
What is the current status of trial NCT01401985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2011-10. Estimated completion is 2012-08.
What conditions does trial NCT01401985 study?
This clinical trial studies the following conditions: Opioid-induced Constipation.
What interventions are being tested in trial NCT01401985?
The interventions under investigation include: Placebo (DRUG), TD-1211 (DRUG).
Who is sponsoring clinical trial NCT01401985?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01401985 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-induced Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
RECRUITING
-
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
COMPLETED · Phase 3
-
Compassionate Use Study of Methylnaltrexone
COMPLETED · NA
-
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
COMPLETED · Phase 4
-
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.